Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 5959-5966

  García Salguero, Cristina ^a   Rodríguez Avial, Iciar ^a   Picazo, Juan J ^a   Culebras, Esther ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PLAZOMICIN; TIGECYCLINE; TOBRAMYCIN; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; ANTIINFECTIVE AGENT; SISOMICIN; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; DISK DIFFUSION; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INTENSIVE CARE UNIT; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; CROSS INFECTION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CROSS INFECTION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; SISOMICIN; THIENAMYCINS;

EID: 84942239862     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00873-15     Document Type: Article

References (27)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
3. Fernandez Cuenca F, Sanchez Mdel C, Caballero-Moyano FJ, Vila J, Martinez-Martinez L, Bou G, Bano JR, Pascual A. 2012. Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumannii. Int J Antimicrob Agents 39:472-477. http://dx.doi.org/10.1016/j.ijantimicag.2012.01.015.
4. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, Kollef MH. 2010. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 54:1742-1748. http://dx.doi.org/10.1128/AAC.01365-09.
5. America Thoracic Society, Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
6. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M. 2006. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53:274-278. http://dx.doi.org/10.1016/j.jinf.2005.11.019.
7. Landman D, Kelly P, Backer M, Babu E, Shah N, Bratu S, Quale J. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 66:332-334. http://dx.doi.org/10.1093/jac/dkq459.
8. Walkty A, Adam H, Baxter M, Denisuik A, Lagace-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. 2014. In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother 58:2554-2563. http://dx.doi.org/10.1128/AAC.02744-13.
9. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58:4443-4451. http://dx.doi.org/10.1128/AAC.00099-14.
10. Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, Panagea T, Argyropoulou A, Stefanou I, Plakias G, Giamarellou H, Petrikkos G. 2012. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 24:191-194. http://dx.doi.org/10.1179/1973947812Y.0000000015.
11. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2012. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 10:459-473. http://dx.doi.org/10.1586/eri.12.25.
12. Tenover FC, Tickler I, Armstrong ES, Kubo A, Lopez S, Persing DH, Miller GH. 2011. Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int J Antimicrob Agents 38:352-354. http://dx.doi.org/10.1016/j.ijantimicag.2011.05.016.
13. Álvarez-Buylla A, Picazo JJ, Culebras E. 2013. Optimized method for Acinetobacter species carbapenemase detection and identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 51:1589-1592. http://dx.doi.org/10.1128/JCM.00181-13.
14. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
15. European Committee on Antimicrobial Susceptibility Testing. 2015. Clinical breakpoints. http://www.eucast.org/clinical-breakpoints/.
16. Akers KS, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, Guymon C, Keen EF, III, Robinson BJ, Mende K, Murray CK. 2010. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J Clin Microbiol 48:1132-1138. http://dx.doi.org/10.1128/JCM.02006-09.
17. Haldorsen BC, Simonsen GS, Sundsfjord A, Samuelsen O. 2014. Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6′)-Ib. Diagn Microbiol Infect Dis 78:66-69. http://dx.doi.org/10.1016/j.diagmicrobio.2013.10.001.
18. Eliopoulos GM, Moellering CR. 1996. Antimicrobial combinations, p 330-396. In Lorian V (ed), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, MD.
19. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 57:573-576. http://dx.doi.org/10.1093/jac/dki477.
20. Tängdén T, Hickman RA, Forsberg P, Lagerback P, Giske CG, Cars O. 2014. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58:1757-1762. http://dx.doi.org/10.1128/AAC.00741-13.
21. Vakulenko SB, Mobashery S. 2003. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16:430-450. http://dx.doi.org/10.1128/CMR.16.3.430-450.2003.
22. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, Pancholi P. 2010. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:4678-4683. http://dx.doi.org/10.1128/AAC.00497-10.
23. Lee HY, Chen CL, Wang SB, Su LH, Chen SH, Liu SY, Wu TL, Lin TY, Chiu CH. 2011. Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications. Int J Antimicrob Agents 37:302-308. http://dx.doi.org/10.1016/j.ijantimicag.2010.12.015.
24. Ikonomidis A, Neou E, Gogou V, Vrioni G, Tsakris A, Pournaras S. 2009. Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii. J Clin Microbiol 47:4055-4059. http://dx.doi.org/10.1128/JCM.00959-09.
25. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. 2014. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 43:370-374. http://dx.doi.org/10.1016/j.ijantimicag.2013.12.010.
26. Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A. 2014. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43:378-382. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.016.
27. Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, Wang LR, Ko WC. 2007. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27:1506-1511. http://dx.doi.org/10.1592/phco.27.11.1506.